Norman Junge1, Miriam Tiedau2, Murielle Verboom3, Michael Hallensleben3, Rainer Blasczyk3, Jerome Schlue4, Imeke Goldschmidt2, Eva-Doreen Pfister2, Ulrich Baumann2. 1. Pediatric Gastroenterology and Hepatology, Department of Paediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Carl- Neuberg-Str 1, 30625, Hannover, Niedersachsen, Germany. Junge.Norman@mh-hannover.de. 2. Pediatric Gastroenterology and Hepatology, Department of Paediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Carl- Neuberg-Str 1, 30625, Hannover, Niedersachsen, Germany. 3. Institute for Transfusion Medicine, Hannover Medical School, Carl- Neuberg-Str 1, 30625, Hannover, Niedersachsen, Germany. 4. Institute for Pathology, Hannover Medical School, Carl- Neuberg-Str 1, 30625, Hannover, Niedersachsen, Germany.
Abstract
UNLABELLED: An association of human leukocyte antigen (HLA) class II alleles with autoimmune conditions is increasingly being used for diagnostic purposes. The aim of our study was to examine whether HLA class II alleles in pediatric-onset autoimmune liver disease (pAILD) may serve as diagnostic markers and if they correlate with clinical outcome parameters. HLA-DRB1 alleles of 76 children with pAILD (autoimmune hepatitis [AIH], autoimmune sclerosing cholangitis [AISC], primary sclerosing cholangitis [PSC]) and of 50 healthy blood donors as control group were analyzed retrospectively. Diagnosis of these patients was confirmed by the autoimmune hepatitis score including liver histology, which has been re-evaluated by a blinded liver pathologist, and by bile duct imaging, as appropriate. Our results showed significant association of HLA-DRB1*03 with AIH1 and AISC with 82 % specificity for AIH. For pAILD (excluding AIH2), HLA-DRB1*03 homozygosity had specificity of 98 %, whereas sensitivity is low. Remission in HLA-DRB1*03-positive patients appears to be less likely. HLA-DRB1*13 is significantly associated with PSC and also with AIH1. CONCLUSION: HLA-DRB1 alleles provide supportive information for diagnostic workup in patients with liver disease, but they were not suitable for differentiation within pAILD. Their prognostic value could be helpful but needs to be evaluated further. WHAT IS KNOWN: • HLA-DRB1*03 is NOT associated with pediatric AIH in a previous national study. • In other studies, HLA-DRB1*03 is associated with AIH1. • HLA-DRB1*13 is associated with PSC. • HLA-DRB1*04 is described as protective for AILD. What is New: • HLA-DRB1 four-digit typing for all alleles and for all subgroups of pAILD combined with re-assessment of liver histology • HLA-DRB1*03:01 is associated with pediatric AIH1 and AISC. • HLA-DRB1*03:01 appears to be a prognostic marker. • HLA-DRB1*13:01 is associated with pediatric AIH1 in mixed ethnicity cohort. • HLA-DRB1*04 does not show any protective effect for pAILD.
UNLABELLED: An association of human leukocyte antigen (HLA) class II alleles with autoimmune conditions is increasingly being used for diagnostic purposes. The aim of our study was to examine whether HLA class II alleles in pediatric-onset autoimmune liver disease (pAILD) may serve as diagnostic markers and if they correlate with clinical outcome parameters. HLA-DRB1 alleles of 76 children with pAILD (autoimmune hepatitis [AIH], autoimmune sclerosing cholangitis [AISC], primary sclerosing cholangitis [PSC]) and of 50 healthy blood donors as control group were analyzed retrospectively. Diagnosis of these patients was confirmed by the autoimmune hepatitis score including liver histology, which has been re-evaluated by a blinded liver pathologist, and by bile duct imaging, as appropriate. Our results showed significant association of HLA-DRB1*03 with AIH1 and AISC with 82 % specificity for AIH. For pAILD (excluding AIH2), HLA-DRB1*03 homozygosity had specificity of 98 %, whereas sensitivity is low. Remission in HLA-DRB1*03-positive patients appears to be less likely. HLA-DRB1*13 is significantly associated with PSC and also with AIH1. CONCLUSION:HLA-DRB1 alleles provide supportive information for diagnostic workup in patients with liver disease, but they were not suitable for differentiation within pAILD. Their prognostic value could be helpful but needs to be evaluated further. WHAT IS KNOWN: • HLA-DRB1*03 is NOT associated with pediatric AIH in a previous national study. • In other studies, HLA-DRB1*03 is associated with AIH1. • HLA-DRB1*13 is associated with PSC. • HLA-DRB1*04 is described as protective for AILD. What is New: • HLA-DRB1 four-digit typing for all alleles and for all subgroups of pAILD combined with re-assessment of liver histology • HLA-DRB1*03:01 is associated with pediatric AIH1 and AISC. • HLA-DRB1*03:01 appears to be a prognostic marker. • HLA-DRB1*13:01 is associated with pediatric AIH1 in mixed ethnicity cohort. • HLA-DRB1*04 does not show any protective effect for pAILD.
Authors: M Pando; J Larriba; G C Fernandez; H Fainboim; M Ciocca; M Ramonet; I Badia; J Daruich; J Findor; H Tanno; C Cañero-Velasco; L Fainboim Journal: Hepatology Date: 1999-12 Impact factor: 17.425
Authors: F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya Journal: J Hepatol Date: 1999-11 Impact factor: 25.083
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Pengyun Wang; Haibin Su; James Underhill; Laura J Blackmore; Maria Serena Longhi; Tassos Grammatikopoulos; Elizabeth Veronica Okokon; Edward T Davies; Diego Vergani; Giorgina Mieli-Vergani; Yun Ma Journal: J Pediatr Gastroenterol Nutr Date: 2014-04 Impact factor: 2.839
Authors: Yun Ma; Haibin Su; Marianne Samyn; Diego Vergani; Giorgina Mieli-Vergani; Muhammed Yuksel; Maria Serena Longhi; Mark J McPhail; Pengyun Wang; Sanjay Bansal; Guan-Wee Wong; Jonathon Graham; Li Yang; Richard J Thompson; Derek G Doherty; Nedim Hadzic; Yoh Zen; Alberto Quaglia; Michael A Heneghan Journal: Hepatology Date: 2021-06-21 Impact factor: 17.425
Authors: Jana Diestelhorst; Norman Junge; Danny Jonigk; Jerome Schlue; Christine S Falk; Michael P Manns; Ulrich Baumann; Elmar Jaeckel; Richard Taubert Journal: Sci Rep Date: 2018-01-11 Impact factor: 4.379
Authors: Jana Diestelhorst; Norman Junge; Jerome Schlue; Christine S Falk; Michael P Manns; Ulrich Baumann; Elmar Jaeckel; Richard Taubert Journal: PLoS One Date: 2017-07-11 Impact factor: 3.240
Authors: Richard Taubert; Jana Diestelhorst; Norman Junge; Martha M Kirstein; Sven Pischke; Arndt Vogel; Heike Bantel; Ulrich Baumann; Michael P Manns; Heiner Wedemeyer; Elmar Jaeckel Journal: Sci Rep Date: 2018-11-28 Impact factor: 4.379